

<b>FORM PTO-1449</b> <b>INFORMATION DISCLOSURE STATEMENT</b>				<b>SERIAL NO.</b>		<b>To be assigned</b>	
				<b>FILING DATE</b>		<b>Concurrently herewith</b>	
				<b>APPLICANT</b>		<b>Desmond John BEST</b>	
				<b>GROUP</b>		1625	
				<b>EXAMINER</b>		W DAVIS	
				<b>ATTORNEY DOCKET NO.</b>		P33128USw	
<b>U.S. PATENT DOCUMENTS</b>							
<b>Examiner Initials</b>		<b>Patent Number</b>	<b>Issue Date</b>	<b>Name</b>	<b>Class</b>	<b>Subclass</b>	<b>Filing Date If Appropriate</b>
Continue on page							
<b>FOREIGN PATENT DOCUMENTS</b>							
		<b>Document Number</b>	<b>Publication Date</b>	<b>Country</b>	<b>Class</b>	<b>Subclass</b>	<b>Translation Yes   No</b>
	1.	WO02076925	10/3/2002	PCT			
	2.	WO0224695	3/28/2002	PCT			
	3.	WO0212190	2/14/2002	PCT			
	4.	WO0006254	2/10/2000	PCT			
	5.	WO0123374	4/5/2001	PCT			
	6.	WO01066520	9/13/2001	PCT			
	7.	WO02094788	11/28/2002	PCT			
	8.	WO9850363	11/12/1998	PCT			
	9.	WO9850364	11/12/1998	PCT			
	10.	WO9840385	9/17/1998	PCT			
	11.	WO0166534	9/13/2001	PCT			
	12.	WO9534540	12/21/1995	PCT			
Continue on page							
<b>OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)</b>							
	13.	ADCOCK et al., "Substituent Effects of <sup>19</sup> F Nuclear Magnetic Resonance: Polar and π-Electron Effects", Aust. J. Chem 29:2571-2581 (1976).					
	14.	AUSTIN et al., "Novel 2,3,4,5-Tetrahydro-1H-3-benzazepines with High Affinity and Selectivity for the Dopamine <sub>3</sub> Receptor", Bioorg Med Chem Lett 10:2553-2555 (2000).					
	15.	AUSTIN et al., "Design and Synthesis of Novel 2,3-Dihydro-1H-isoindoles with High Affinity and Selectivity for the Dopamine D <sub>3</sub> Receptor," Bioorg Med Chem Lett 11:685-688 (2001).					
	16.	FRANKEL, Chemische Berichte Vol. 33 pp. 2811 (1900).					
	17.	GIOVANNINI et al., "Effects of histamine H <sub>3</sub> receptor agonists and antagonists on cognitive performance and scopolamine-induced amnesia," Behavirural Brain Res. 104:147-155 (1999).					
	18.	LEURS et al., "Therapeutic potential of histamine H <sub>3</sub> receptor agonists and antagonists," TiPS 19:177-183 (May 1998).					
	19.	LOVENBERG et al., "Cloning and Funcational Expression of the Human Histamine H <sub>3</sub> Receptor," Molecular Pharmacology 55:1101-1107 (1999).					
	20.	ONODERA and WATANABE, "Histamine H <sub>3</sub> Antagonists as Potential Therapeutics in the CNS," ed Leurs and Timmerman, pp255-267, Elsevier Science B.V. (1998).					
	21.	RICE et al., "Synthesis of Fluorinated Derivatives of Benzo[k]fluoranthene and indeno[1,2,3-cd]pyrene and 8,9-Dihydro-8,9-epoxybenzo[k]fluoranthene," J. Org. Chem 53:1775-1779 (1988).					
	22.	SCHLICKER et al., "Modulation of neurotransmitter release via histamine H <sub>3</sub> heteroreceptors," Fundam Clin Pharmacol 8:128-137 (1994).					
	23.	STOKKER, "Preparation of 1,2,3,4-Tetrahydroisoquinolines Lacking Electron Donating Groups - An Intramolecular Cyclization Complementary to the Pictet-Spengler Reaction," Tetrahedron Letters 37(31):5453-5456 (1996).					
	24.	WALSH et al., "Synthesis and Antiallergy Activity of 4-(Diarylhydroxymethyl)-1-[3-(aryloxy)propyl]piperidines and Structurally Related Compounds," J. Med. Chem 32:105-118 (1989).					
25.	WEINSTOCK et al., "Synthesis and Renal Vasodilator Activity of Some Dopamine Agonist 1-Aryl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diols: Halogen and Methyl Analogues of Fenoldopam," J. Med. Chem 29:2315-2325 (1986).						
Continue on page							
<b>EXAMINER</b> <i>Linna W Davis</i>					<b>DATE CONSIDERED</b> 12/31/2007		
<b>EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** ( Not for submission under 37 CFR 1.99)

Application Number	10532373
Filing Date	2005-04-21
First Named Inventor	Best
Art Unit	4614-1625
Examiner Name	(not yet assigned) ZNDAYS
Attorney Docket Number	P33128USw

## **U.S. PATENTS**

[Remove](#)

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

[Add](#)

## **U.S. PATENT APPLICATION PUBLICATIONS**

[Remove](#)

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

[Add](#)

## **FOREIGN PATENT DOCUMENTS**

[Remove](#)

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> j	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
gnd	1	9221476	JP		1997-08-26	Otsuka Pharmaceutical Co. Ltd.	(Abstract only)	<input checked="" type="checkbox"/>
gnd	2	2004035544	WO	A1	2004-04-29	Glaxo Group Ltd.		<input type="checkbox"/>
gnd	3	2004035556	WO	A1	2004-04-29	Glaxo Group Ltd.		<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10532373
Filing Date		2005-04-21
First Named Inventor	Best	
Art Unit	1814 1625	
Examiner Name	(not yet assigned) ZANDAV 15	
Attorney Docket Number	P33128USw	

mpk	4	2004037800	WO	A1	2004-05-06	Glaxo Group Ltd.	<input type="checkbox"/>
mpk	5	1262475	EP	A1	2002-12-04	Ono Pharmaceutical Co., Ltd.	<input type="checkbox"/>
mpk	6	2004026305	WO	A1	2004-04-01	Eli Lilly & Company	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
	1		<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature	Zina N Davis	Date Considered	12/31/2007
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.